Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
VEGFR tyrosine-kinase inhibitor

Tivozanib (Specialist drug)

Brand names: Fotivda

Tivozanib is an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor used in the first-line treatment of advanced renal cell carcinoma. It is a specialist drug initiated under oncology supervision.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits VEGF receptors, blocking tumour angiogenesis and thereby restricting tumour blood supply and growth.

Prescribing in practice

  • Hypertension is very common and can be severe, so blood pressure must be controlled before starting and monitored throughout treatment.
  • It carries risks of bleeding, arterial and venous thromboembolic events, and impaired wound healing, so it should be withheld around surgery.
  • It can cause hypothyroidism and proteinuria, and interacts with strong CYP3A4 modulators.

Monitoring

Monitor blood pressure, thyroid function and urinary protein, and review for bleeding or thromboembolic symptoms during treatment.

Counselling the patient

  • Have your blood pressure checked regularly and report severe headaches or visual disturbance.
  • Tell your team before any planned surgery or dental procedures.
  • Report unusual bleeding, swelling or signs of a clot such as a painful swollen leg or breathlessness.

Evidence & guidelines

Tivozanib was evaluated against sorafenib in advanced renal cell carcinoma in the TIVO-1 and TIVO-3 trials supporting its licensed use.

Reference: NICE TA512; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways